Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Medical - Instruments & Supplies

Healthcare
$28.29 -0.37%

-$0.07 today

Market cap
$1.69B
Beta
0.83
P/E (TTM)
-6.9
EPS (TTM)
-$2.74
52W Low $13.25High $30.00

Volume 0.44M

Average 0.33M

KMTS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Kestra Medical Technologies, Ltd.NASDAQ: KMTS

Cash & Equivalents · Q3 FY2026 · quarter ended Jan 2026

Cash & equivalents rises 436.0% from a year ago

Cash & equivalents stood at $291.32M at the end of Q3 FY2026, up 436.0% from a year earlier and up 66.1% from the prior quarter.

Context

  • Cash & equivalents amounted to 76.8% of total assets at the end of Q3 FY2026, up 26.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +436.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJan 2026
$291.32M+66.1% QoQ
Last fiscal yearApr 2025
$237.6M+2780.3% YoY
Year agoJan 2025
$54.35M+436.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+436.0%——
1 year+2780.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
237.6M USD
Year-over-year change
+2780.3%
5-year CAGR
+110.4%

Cash & Equivalents vs competitors

How KMTS compares with its peers on the latest reported figures

  • KMTS's Jan 2026 cash & equivalents of $291.32M is the 2nd highest of the 3 companies compared; the peer median is $233.51M.
  • Its year-over-year change of +436.0% is the highest of 3, against a peer median of +12.4%.
  • Cash & equivalents amounts to 76.8% of total assets for KMTS, versus a peer median of 54.3%.
KMTS Competitors Peer median
Cash & Equivalents for KMTS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRTCiRhythm Technologies, Inc.Sep 2026$394.72M +54.4%+44.1%36.2%
KMTSKestra Medical Technologies, Ltd.Jan 2026$291.32M +436.0%—76.8%
CVRXCVRx, Inc.Mar 2026$72.3M -29.6%-10.7%72.5%
Peer median (excluding KMTS) $233.51M+12.4%+16.7%54.3%

Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2020
Apr 2020
FY2021
Apr 2021
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Cash & Equivalents5.76M24.34M14.81M8.25M237.6M
Short-term Investments00000
Net Receivables002.11M2M8.08M
Inventory002.11M3.29M6.57M
Other Current Assets209K1.35M(1.74M)419K1.69M
Total Current Assets6.17M26.2M18.42M14.91M255.33M
Property, Plant & Equipment (Net)1.13M3.08M16.72M28.39M36.91M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets580K1.24M3.51M2.65M3.51M
Total Non-current Assets1.71M4.33M20.23M31.04M40.42M
Total Assets7.87M30.52M38.66M45.95M295.74M
Account Payables1.83M1.7M6.16M23.89M23.96M
Short-term Debt0020.45M0187K
Tax Payables68K42K215K234K0
Deferred Revenue00000
Other Current Liabilities004.67M6.19M8.49M
Total Current Liabilities4.02M6.61M36.74M32.97M37.98M
Long-term Debt020.24M17.32M42.54M41.1M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0360K102.17M177.19M8.24M
Total Non-current Liabilities022.15M119.5M222.36M52.36M
Total Liabilities4.02M28.76M156.23M255.33M90.34M
Common Stock1K1K1K1K51.35M
Retained Earnings(135.98M)(170.08M)(312.32M)(406.44M)(520.25M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity3.86M1.77M(117.58M)(209.38M)205.41M
Total Debt452K22.85M39.13M45.17M44.31M
Net Debt(5.3M)(1.49M)24.32M36.92M(193.28M)

Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Intrinsic Alpha fair value

Locked

Current Price

$28.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.